OncoSec’s OMS ElectroOncology Technology Platform featured in Medical Device & Diagnostic Industry

SAN DIEGO, CA, February 29, 2012 — OncoSecMedical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been featured in an editorial piece in the March issue of Medical Device & Diagnostic Industry outlining development of its technology platform for treatment of rare and deadly skin cancers.

The article titled “OncoSec Could Revolutionize Oncology Therapy,” details the company’s promising OMS ElectroOncology treatment platform, as well as the on-going Phase II clinical studies in metastatic melanoma and Merkel cell carcinoma. The article also notes the company’s upcoming milestones for 2012.

To read the article in its entirety, please visit the following link:
http://www.mddionline.com/article/oncoSec-could-revolutionize-oncology-therapy

Medical Device & Diagnostic Industry (MD&DI) is a monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnosticproducts. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. Readers are professional personnel in product R&D, design, manufacturing, quality assurance, regulatory affairs, and corporate management. Worldwide circulation is approximately 50,500.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Clinical Trial Designed to Validate Strong Safety and Efficacy Results Demonstrated in Phase I Study

SAN DIEGO, CA, February 28, 2012 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Investigational Review Board (IRB) approval has been received by the University of California San Francisco and the first patient has been dosed for a Phase II clinical trial evaluating OncoSec’s OMS ElectroImmunotherapy for the treatment of advanced stage cutaneous and in-transit metastatic melanoma. UCSF investigators are actively recruiting for this clinical trial.

“Results from our open-label Phase I study demonstrated that DNA IL-12 and electroporation has the potential to establish a new standard of care for the treatment of late-stage metastatic melanoma,” said Punit Dhillon, President and CEO of OncoSec. “With immune response results from this Phase II study expected in the second half of 2012, we are confident this study willvalidate the value of OMS ElectoImmunotherapy.”

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

OMS ElectroImmunotherapy utilizes OncoSec’s proprietary technology to deliver a DNA-based cytokine coded for the immune stimulatingagent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using OMS ElectroImmunotherapy to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, February 13, 2012 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec’s OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC). The clinical trial is designed to test DNA IL-12 administered using OncoSec’s Oncology Medical System (a novel treatment approach for immunotherapy (referred to as OMS ElectroImmunotherapy), in patients with local and distant Merkel cell carcinoma.

A total of up to 15 patients with local and distant Merkel cell carcinoma will be enrolled in this Phase II, single-arm, open-label multi-center study. The trial is designed to assess the clinical and biologic effects ofincreased local expression of IL-12 protein in the tumor microenvironment following treatment with OMS ElectroImmunotherapy. It is anticipated that marked local expression of IL-12 in the tumor will induce an immunologic response in the tumor microenvironment, which may result in clinical benefit for the patient. Investigators at the University of Washington, a world leader in the treatment of Merkel cell carcinoma, have received Investigational Review Board (IRB) approval and will continue recruitment for this clinical trial as the lead enrollment center. The first patient has been enrolled and has successfully completed the first treatment on January 6, 2012.

“We were impressed by the results of the Phase I study in malignant melanoma patients and strongly believe that OMS ElectroImmunotherapy will be especially effective in an immunogenic cancer such as Merkel cell carcinoma,” commented Dr. Shailender Bhatia, principal investigator at the University of Washington. Dr. Paul Nghiem, co-investigator at the University of Washington, added, “Our clinical and research teams have been working with Merkel cell carcinoma for many years, and we are delighted that OncoSec is now taking the industry lead in developing a cancer immunotherapy for this deadly disease.”

Punit Dhillon, President and CEO of OncoSec, said, “The University of Washington is a leading institution in the treatment and research of Merkel cell carcinoma, and patients with this rare and deadly skin cancer have few treatment options. This new clinical study is the only active immunotherapy trial that is focused specifically on this disease.”

OMS ElectroImmunotherapy utilizes OncoSec’s proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The Oncology Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using OMS ElectroImmunotherapy to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

NUMBERS ARE ONLY PART OF THE STORY
Numbers are important. They can be compared against others and tell us how far we have come and how far we have to go. Numbers help us measure our goals and aspirations, and show the world how we intend to reach them. They estimate odds and probabilities and they calculate results. They are necessarily impartial, rational and dispassionate.

But numbers only tell half the story.

They will never be able to put a value on the loss of a loved one, or convey the appreciation for every battle that is won against cancer. However, the largest number would still be too small to measure an empty space in a family photograph.

FROM BENCH TO BEDSIDE
At OncoSec, our dedication to research and development is underpinned by the belief that behind every statistic is a life, and behind every estimate, hope. These principles have guided our work – from a product based clinical development plan and enhancing our capacity to strengthening the scope and depth of our team.

We are committed to improving the quality of life for patients living with deadly skin cancers by providing them with safer and more effective approaches to treating these terrible diseases. The patient is our focus and our path has never been clearer as we move closer than ever to making our commitment a reality.

In less than one year, OncoSec not only initiated and completed the formation of the Company, but also committed to three Phase II clinical studies in rare and deadly skin cancers with significant unmet medical needs. This important milestone was the pinnacle of a number of accomplishments made throughout 2011 that advanced OncoSec from a start-up to a clinical-stage company.

2011 IN REVIEW
The formation of OncoSec in 2011 occurred through the acquisition of certain non-DNA vaccine technologies and intellectual property assets relating to the Company’s OMS ElectroOncology therapies for treating solid tumor cancers. With seed capital secured, the Company quickly moved to attract and acquire an experienced and respected management team and scientific and clinical advisory board.

The Company then established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. OMS ElectroImmunotherapy uses electroporation to deliver, directly into the patient’s own cells, a gene, which expresses interleukin-12, a potent, naturally occurring protein that is central to the regulation of the body’s anti-cancer immune function. Preclinical and Phase I studies have shown that the therapy is safe, without toxic side effects, and has resulted in immune responses that produced both a local and systemic response against cancerous lesions. Positive clinical data of DNA-based IL-12, the first-ever to demonstrate electroporation-mediated delivery of a DNA plasmid designed to express a therapeutic protein in humans, was presented at the 2011 Annual Meeting of the American Society of Clinical Oncology. In the Phase I human study, 15% of patients demonstrated 100% clearance of distant, untreated metastatic melanoma (stage III/IV) tumors; in retrospect only 0.25% would be expected to spontaneous resolve on their own if left untreated. If OncoSec’s Phase II trials further validate this evidence, the DNA-based IL-12 ElectroImmunotherapy platform would represent an important advancement in the treatment of both local and metastatic cancers. All three Phase II studies will be physician-sponsored clinical trials.

This past year also demonstrated the Company’s ability to continue to create value from its advanced-stage OMS ElectroChemotherapy program for the treatment of primary and recurrent localized solid tumors. Since the acquisition of a clinical data set of over 400 patients, OncoSec has compiled, reviewed, and analyzed the data and presented preliminary results from previous Phase IV European head & neck cancer trials and a Phase I/II breast cancer trial. The preliminary data sets from the completed Phase III recurrent head and neck cancer studies carried out in the U.S. and a comprehensive review of the Phase IV European trials in recurrent and primary skin cancers and head & neck cancer are now being analyzed. The Company expects to share this information with potential partners for the continued development of this program.

ON THE FUTURE, PATIENTS – AND NUMBERS
While the near-term outlook for OncoSec is exciting, the long-term outlook may be even brighter. Our platform technology is novel and unique, and data from our OMS ElectroOncology therapies are first-in-class. Over the next 12 months we expect to have interim clinical data from all three of our Phase II trials. We have successfully made the transition to a clinical development company and are well positioned to capitalize on the opportunities for growth ahead of us.

HOW?
The Company will continue to build product value through next generation devices and drugs and generate additional intellectual property organically or through other in-licensing opportunities. In 2011, OncoSec established in-house capabilities to build, maintain and develop its own devices. In 2012, the Company expects to boost its capabilities by meeting additional stringent quality assurance standards and increasing manufacturing capabilities for its ongoing and future clinical trials through additional efficiencies and ability to scale up production as needed to support potential partners.

At OncoSec, we believe 2012 will continue the momentum gained in 2011: by maintaining a lean enterprise through outsourcing and cash flow management, while remaining flexible enough to respond to emerging opportunities; by collaborating with partners such as the University of California San Francisco, the University of Washington and the Fred Hutchinson Cancer Center in order to strengthen our treatment platforms; by creating value from our late-stage OMS ElectroChemotherapy program through potential partnering deals with regional or global partners; and by focusing on the health of the patient.

With our clinical studies off the ground, we look forward to treating the first patient with DNA-based IL-12 and moving ever closer to being able to improve lives with a potentially revolutionary treatment that could offer greater efficacy and safety than existing therapies. That we have advanced so far towards our goal underscores the hard work of the entire OncoSec team, scientific advisors, the Board of Directors, and the tremendous support of our investors. We are dedicated to bringing the entirety of our resources and expertise to try and meet the expectations of our shareholders and patients around the world.

February 3, 2012

Punit Dhillon
President & CEO

This letter contains certain forward-looking statements relating to our plans to develop our OMS ElectroOncology therapies. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that Phase I clinical results referenced in this letter may not be indicative of results achievable from testing in Phase II clinical trials) and the other factors set forth in detail in our Annual Report on Form 10-K for the year ended July 31, 2011 and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products. We encourage our shareholders to carefully review the section entitled “Risk Factors” in the Annual Report with which this letter is provided.

SAN DIEGO, CA, January 24, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Michael Cross, Ph.D., Chief Business Officer at OncoSec, will be presenting at the World Cancer Immunotherapy Conference in San Diego, January 25-26, 2012.

World Cancer Immunotherapy Conference
Hilton San Diego Gaslamp Quarter
401 KStreet, San Diego, CA
United States 92101
January 25-26, 2012

OncoSec Presentation
January 25, 2012
3:45pm PT

The World Cancer Immunotherapy Conference is bringing together leading scientists and C-Level executives from across the globe topresent research, case studies and viewpoints on various topics integral to a better understanding of the challenges and opportunities facing developers of therapeutic cancer vaccines.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

OncoSec – Positive Phase IV ElectroChemotherapy Clinical Data

OncoSec has continued to demonstrate a commitment to achieving our corporate milestones and confirming the company’s urgency for developing revolutionary targeted therapies using its proprietary electroporation delivery system, the OncoSec Medical System, or OMS. With our recent $7.75 million financing we are now poised to focus our resources on exceeding expectations and continuing to drive value from our novel OMS treatment platforms.

OMS ElectroChemotherapy: Targeted Ablation of Solid Tumor Cancers

Today, we announced positive data from our late-stage Phase IV pre-marketing study conducted in Europe at leading clinical centers of excellence using OncoSec’s OMS ElectroChemotherapy treatment platform for primary and recurrent squamous cell carcinoma of the head and neck (HNSCC). Click here for a full copy of the press release.

Interim analysis of this study indicated that the primary endpoint of 8-month local tumor control rate for primary and recurrent HNSCC was excellent with 46/49 (94%) and 12/21(57%) respectively. In addition, the secondary endpoint of preservation of organ function and appearance using established quality of life instruments demonstrated a positive outcome. The functional outcome measurement to evaluate quality of life, specifically any deterioration of swallowing function, normalcy of diet and eating in public was assessed by the subjective Performance Status Scale for Head and Neck cancer (PSSHN) and general QOL by the European Organization for Research and Treatment of Cancer Core QOL questionnaire (EORTC QLQ). HNSCC patients showed a mean overall score of 264 at baseline vs. 249 at 8 months (p=0.3412) indicating no significant difference in quality of life at 8 months following treatment with OMS ElectroChemotherapy, therefore providing an advantage in maintaining quality of life. Furthermore, evaluation of safety using the OMS ElectroChemotherapy for this patient population demonstrated that the treatment was safe and well-tolerated with no grade three or higher adverse events related to treatment during this study.

Secondary endpoints evaluated for this trial included Pharmacoeconomic factors (hospital costs, extent of medical interventions, medication use) and performance of the OncoSec Medical System and applicator. This data is being summarized in combination with the above results for final publication.

The impressive quality of life outcomes in conjunction with strong local tumor control responses are significant: the majority of patients treated in this study had advanced complicated tumors and the only alternative therapy would have been extensive surgery, with potential post-operative radiotherapy. Surgery may have precipitated collateral damage to surrounding tissues and vital structures. While post-treatment care could repair some of this damage, it may also result in further quality of life, physical and emotional burden on the patient and significant additional treatment costs.

In addition to these clinical results, we are preparing to present data from our Phase III head and neck cancer study carried out in the United States. This study was a randomized trial comparing preservation of function status after either OMS ElectroChemotherapy or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the head and neck. These results will be presented at:

The 8th International Head and Neck Cancer Conference
Toronto Convention Center
Toronto, Canada
July 21-25, 2012

Poster Session
“Interim analysis of two randomized Phase 3 trials comparing electrochemotherapy to surgery in recurrent head and neck cancer”

OMS ElectroImmunotherapy: On-going Clinical Trials for Rare and Deadly Skin Cancers

Two Phase II clinical trials for metastatic melanoma and Merkel cell carcinoma are now underway, and several patients in both trials have already been dosed. We expect our third Phase II trial for cutaneous T-cell lymphoma to be initiated in the coming weeks. We expect enrollment for these trials to continue through 2012, however, preliminary results will be shared before the end of the year.

The media has picked up the enthusiasm for our clinical trials and technology with several news outlets covering stories about the company. Below is a sample of OncoSec’s recent news coverage:

San Diego Business Journal– The article, titled “OncoSec Inches Ahead on Skin Cancer Zapping Technology” discusses OncoSec’s development plan, highlighting the company’s OMS ElectroImmunotherapy program for the treatment of Merkel cell carcinoma, metastatic melanoma and cutaneous T-cell lymphoma. This article is only available online to subscribers of the San Diego Business Journal

The Journal- The article, titled “Fighting skin cancer with electroimmunotherapy,” outlines the rationale for the Phase II Merkel cell carcinoma study and describes the urgent need for a new therapy for this patient population.

Today’s Medical Developments– The article, titled “A Novel Delivery System,” details the components and processes governing use of the novel OncoSec Medical System (OMS) technology platform, which leverages electroporation technology to target tumors and deliver powerful cancer therapeutic agents without affecting surrounding healthy tissue.

Medical Device and Diagnostic Industry– The article titled “OncoSec Could Revolutionize Oncology Therapy,” details the company’s promising OMS ElectroOncology treatment platform, as well as the on-going Phase II clinical studies in metastatic melanoma and Merkel cell carcinoma.

If you have any questions about OncoSec or our current activities, please contact us at investors@oncosec.com. Thank you for your support.

Best,

Punit Dhillon
President & CEO

Biomarkers May Facilitate Patient Selection For Treatment of Melanoma, Merkel Cell Carcinoma or Cutaneous T-Cell Lymphoma with OMS ElectroImmunotherapy

SAN DIEGO, CA, November 16, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. Terms of the final agreement have not been released.

The advancement of biomarkers able to display the presence of or change in a biological response such as a protein related to a specific disease has been invaluable in improving patient outcomes in the multi-billion-dollar commercial success of multiple medical therapies. Unfortunately, the discovery of biomarkers in the field of cancer immunotherapy has been elusive. Serametrix has been leading the field in developing validated tests to identify such biomarkers, providing simple and robust methods thatdeliver accurate and reliable results. Using Serametrix’s proprietary Seromic™ Profiling Assay, samples of blood taken from patients in OncoSec’s three clinical studies will be analyzed with the goal of detecting potential predictive biomarkers and provide an understanding of the broad humoral (antibody) anti-tumor response resulting from OncoSec’s immune therapy using DNA IL-12 and electroporation. Identification of a new biomarker(s) may enable the optimal selection of patients most likely to respond to OncoSec’s OMS ElectroImmunotherapy.

“Effective immune monitoring is vital in the clinical development of cancer immunotherapies,” said Henry Hepburne-Scott, Ph.D., Vice President, Business Development for Serametrix Corporation. “Serum antibodies to our panels of tumor antigens have proved valuable for predicting and monitoring patient responses to existing cancer therapies and we are delighted to be working with OncoSec on their exciting pipeline of novel therapies.”

Dr. Adil Daud, principal investigator at the University of California San Francisco for OncoSec’s upcoming melanoma clinical trial, said, “A critical issue in cancer immunotherapy trials is patient selection. Given the complexity of the immune response in cancer, it has been difficult to pinpoint the most appropriate biomarker. This partnership offers an opportunity to develop a biomarker complementary to the clinical activity for DNA IL-12electroporation.”

“By combining OncoSec’s OMS ElectroImmunotherapy with Serametrix’s best-in-class immunoassays, this collaboration places OncoSec at the forefront of immunologic assessment supporting the application of immunotherapies,” said Punit Dhillon, President and CEO of OncoSec. “We aim to define parameters that may ultimately facilitate improved disease outcomes after OMS ElectroImmunotherapy treatment. This accomplishment may also help us accelerate product development.”

About Serametrix Corp.

Serametrix technology measures patients’ humoral and cellular immunity to proprietary panels of tumor antigens. These assays enable discovery and validation of biomarkers that have utility in drug development and clinical applications. For example, monitoring patient reactivity to key antigen panels can provide valuable insight into the effects of drugs on anti-cancer immunity. By combining the knowledge base of best-in-class researchers and clinicians, Serametrix is able to provide a more rational approach to patient treatment.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, November 14, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that Punit Dhillon, President and CEO, will be presenting at the 6th Annual Medical Device Investor Forum in Irvine, California.

6th Annual Medical Device Investor Forum
Hyatt Regency Irvine
17900 Jamboree Road
Irvine, California, USA 92614
November 15, 2011
4:50 pm PST

In its 6th year, the two-day Orange County based conference will bring together industry professionals and investors in an effort to build funding opportunities for medical device innovations. The forum is intended to open up discussion amongst professionals ranging from established business leaders and key investors to early stage startup medical device venture capitalists.

OncoSec will also be attending the American Israeli Medical Association (AIMA) BioMedTech Conference in Los Angeles, CA.

AIMA – BioMedTech Conference
Skirball Cultural Center
2701 Sepulveda Blvd.
Los Angeles, CA 90049
November 15, 2011

About OncoSec Medical Inc. OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, October 20, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies for the treatment of solid tumor cancers, announced today the submission of its Device Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its patented OncoSec Medical System (OMS) which consists of a generator and hand-held applicator. The Company has been developing the OncoSec Medical System as its lead medical device for delivering DNA based cytokines and chemotherapeutic agents for the treatment of solid tumor cancers. In numerous Phase I through Phase IV clinical trials, the OncoSec Medical System has been shown to be both safe and effective for optimizing the cellular uptake of DNA based cytokines or chemotherapeutic agents resulting in improved therapeutic benefits for the patient.

The DMF, which includes technical, manufacturing, clinical and non-clinical information about the OncoSec Medical System, marks an important milestone for the Company. This regulatory filing facilitates FDA review of the complete system when any investigational clinical study application references its use.

“This DMF submission brings the OncoSec Medical System another step closer to becoming the treatment of choice for different types of solid tumor cancers,” stated Punit Dhillon, President and Chief Executive Officer of OncoSec. “In a very short period of time, OncoSec has moved aggressively with its clinical and regulatory strategy, with the DMF being one important piece of that strategy. Moving forward, we will continue to demonstrate the value of our treatment approaches as our clinical studies begin.”

OncoSec plans to initiate three Phase II clinical trials under physician sponsored INDs using the OncoSec Medical System to deliver DNA IL-12: OMS-I100 for the treatment of melanoma; OMS-I120 for the treatment of Merkel cell carcinoma; and OMS-I130 for the treatment of cutaneous T-cell lymphoma.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, October 4, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology™ therapies to treat solid tumor cancers, announced today that the OncoSec Medical System (OMS) devices have been qualified and released and are now ready for shipment to clinical sites in time for the upcoming OMS ElectroImmunotherapy™ clinical trials.

In March 2011 OncoSec acquired the rights to an electroporation delivery technology platform that can be used to efficiently deliver a chemotherapeutic or DNA-based cytokine agent for the treatment of solid tumors, which OncoSec has branded as the OncoSec Medical System (OMS). Since then, projects were initiated to establish engineering and manufacturing capabilities, as well as, transfer and update regulatory, design and manufacturing documentation, including implementing a new quality assurance system. Over the course of five months a manufacturing plan was executed to ensure that the devices acquired by OncoSec were safe and ready for use in clinical trials. The company now has inventory of OMS investigational devices adequate to support known and anticipated clinical study requirements well into 2013. OncoSec’s current infrastructure and facility is designed to support manufacturing, assembly, testing, technical and regulatory support for multiple clinical trials in compliance with FDA and quality systems regulations. The extent of OncoSec manufacturing operations allow the company to build and maintain the current device supply to support on-going and future clinical trials, scale up production as needed as well as design and develop a next generation OMS electroporation system. The company utilizes contract manufacturers for key operations, such as clean room assembly and sterilization, which are not presently economically conducted in-house.

“Since acquiring the technology our team has worked diligently to test, and re-test, the OMS device to ensure that it is safe and ready for in-human use, as well as, manufacture new applicators and applicator handles for the OMS ElectroImmunotherapy™ clinical trials. I am delighted to report that they are now ready for shipment to the clinical sites,” said, Dr. Michael Cross, OncoSec’s Chief Business Officer, “This milestone also highlights the fact that OncoSec now has the in-house capabilities to build, maintain and develop our own devices, while still having the flexibility to outsource specific manufacturing activities, where required, thereby allowing OncoSec to hold strict control over manufacturing costs.”

OncoSec intends to initiate three Phase II clinical trials using the OMS ElectroImmunotherapy™ treatment approach for melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma by the end of October 2011. “The release of these devices is an integral step in our development plan. With the achievement of this milestone, we continue to meet the goals set out by our corporate strategy, and expect to move toward validating the data seen in the Phase I study in our upcoming clinical trials.,” said Punit Dhillon, President and CEO.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


Real Time Web Analytics